Oppenheimer Sees $1 Billion Potential in Passage Bio’s PBFT02 for FTD

Oppenheimer just started coverage on Passage Bio with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026.